KLHDC8B

Summary

KLHDC8B (kelch domain containing 8B, HGNC:28557) is a protein-coding gene on chromosome 3p21.31, encoding Kelch domain-containing protein 8B (Q8IXV7). Involved in pinching off the separated nuclei at the cleavage furrow and in cytokinesis.

This gene encodes a protein which forms a distinct beta-propeller protein structure of kelch domains allowing for protein-protein interactions. Mutations in this gene have been associated with Hodgkin lymphoma.

Source: NCBI Gene 200942 — RefSeq curated summary.

At a glance

• Gene–disease (curated): classic Hodgkin lymphoma (Limited, GenCC)
• GWAS associations: 14
• Clinical variants (ClinVar): 192 total
• Phenotypes (HPO): 4
• MANE Select transcript: NM_173546

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28557
Approved symbol	KLHDC8B
Name	kelch domain containing 8B
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	MGC35097
Ensembl gene	ENSG00000185909
Ensembl biotype	protein_coding
OMIM	613169
Entrez	200942

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 10 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000332780, ENST00000459846, ENST00000462582, ENST00000471811, ENST00000476495, ENST00000904821, ENST00000904822, ENST00000948545, ENST00000948546, ENST00000948547, ENST00000948548, ENST00000948549, ENST00000948550, ENST00000948551

RefSeq mRNA: 1 — MANE Select: NM_173546 NM_173546

CCDS: CCDS2791

Canonical transcript exons

ENST00000332780 — 6 exons

Exon	Start	End
ENSE00001298839	49175062	49175163
ENSE00001332172	49175605	49176486
ENSE00001904598	49171598	49171685
ENSE00002724455	49172636	49173145
ENSE00003518431	49174239	49174403
ENSE00003685718	49174742	49174966

Expression profiles

Bgee: expression breadth ubiquitous, 247 present calls, max score 98.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.6739 / max 280.1762, expressed in 1588 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36616	11.2286	1541
36615	1.4453	947

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	98.78	gold quality
left adrenal gland cortex	UBERON:0035825	98.77	gold quality
adrenal cortex	UBERON:0001235	98.69	gold quality
adrenal tissue	UBERON:0018303	98.66	gold quality
right adrenal gland	UBERON:0001233	98.64	gold quality
left adrenal gland	UBERON:0001234	98.63	gold quality
apex of heart	UBERON:0002098	98.24	gold quality
left ventricle myocardium	UBERON:0006566	98.15	gold quality
left ovary	UBERON:0002119	98.00	gold quality
adrenal gland	UBERON:0002369	97.96	gold quality
right ovary	UBERON:0002118	97.61	gold quality
cardiac muscle of right atrium	UBERON:0003379	97.55	gold quality
heart left ventricle	UBERON:0002084	97.13	gold quality
cardiac ventricle	UBERON:0002082	97.05	gold quality
lower esophagus mucosa	UBERON:0035834	96.64	gold quality
lower esophagus	UBERON:0013473	96.58	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.58	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.38	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.03	gold quality
myocardium	UBERON:0002349	95.71	gold quality
heart	UBERON:0000948	95.57	gold quality
ovary	UBERON:0000992	95.46	gold quality
right lobe of thyroid gland	UBERON:0001119	94.81	gold quality
heart right ventricle	UBERON:0002080	94.81	gold quality
right atrium auricular region	UBERON:0006631	94.80	gold quality
cardiac atrium	UBERON:0002081	94.79	gold quality
tibialis anterior	UBERON:0001385	94.78	silver quality
esophagus	UBERON:0001043	94.76	gold quality
left lobe of thyroid gland	UBERON:0001120	94.65	gold quality
mucosa of stomach	UBERON:0001199	94.50	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-10	yes	37.92
E-GEOD-93593	yes	6.60
E-ANND-3	yes	2.90
E-MTAB-10137	no	426.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

67 targeting KLHDC8B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-6755-5P	99.95	65.59	464
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-424-5P	99.89	71.90	2641

Literature-anchored findings (GeneRIF, showing 3)

• Depletion of KLHDC8B through RNA interference leads to an increase in binucleated cells, implicating its reduced expression in the formation of classical Hodgkin lymphoma’s signature Reed-Sternberg cell. (PMID:19706467)
• Deficiency of KLHDC8B leads to binucleated cells, implicating its involvement in Reed-Sternberg cell formation (PMID:20107318)
• kelch protein KLHDC8B guards against mitotic errors, centrosomal amplification, and chromosomal instability (PMID:22988245)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Klhdc8b	ENSMUSG00000032609
rattus_norvegicus	Klhdc8b	ENSRNOG00000047867

Paralogs (54): KLHL13 (ENSG00000003096), KLHL20 (ENSG00000076321), KEAP1 (ENSG00000079999), KLHL42 (ENSG00000087448), KLHL22 (ENSG00000099910), KLHL4 (ENSG00000102271), KLHL2 (ENSG00000109466), KLHL5 (ENSG00000109790), BACH2 (ENSG00000112182), KLHL18 (ENSG00000114648), KLHL24 (ENSG00000114796), IVNS1ABP (ENSG00000116679), KLHL12 (ENSG00000117153), KLHL29 (ENSG00000119771), KBTBD7 (ENSG00000120696), KLHL7 (ENSG00000122550), KLHL31 (ENSG00000124743), KLHDC7B (ENSG00000130487), KLHL36 (ENSG00000135686), KLHL8 (ENSG00000145332), KLHL3 (ENSG00000146021), KLHL35 (ENSG00000149243), KLHL1 (ENSG00000150361), BACH1 (ENSG00000156273), KLHL40 (ENSG00000157119), KLHL10 (ENSG00000161594), KLHL21 (ENSG00000162413), KLHDC8A (ENSG00000162873), KBTBD8 (ENSG00000163376), KBTBD6 (ENSG00000165572), KLHL26 (ENSG00000167487), KLHL30 (ENSG00000168427), KBTBD2 (ENSG00000170852), KLHL6 (ENSG00000172578), KLHL15 (ENSG00000174010), KLHL38 (ENSG00000175946), KBTBD11 (ENSG00000176595), KLHDC7A (ENSG00000179023), KLHL28 (ENSG00000179454), KBTBD3 (ENSG00000182359)

Protein

Protein identifiers

Kelch domain-containing protein 8B — Q8IXV7 (reviewed: Q8IXV7)

All UniProt accessions (1): Q8IXV7

UniProt curated annotations — full annotation on UniProt →

Function. Involved in pinching off the separated nuclei at the cleavage furrow and in cytokinesis. Required for mitotic integrity and maintenance of chromosomal stability. Protects cells against mitotic errors, centrosomal amplification, micronucleus formation and aneuploidy. Plays a key role of midbody function involving abscission of the daughter cells during cytokinesis and appropriate chromosomal and nuclear segregation into the daughter cells.

Subcellular location. Cytoplasm. Midbody.

Disease relevance. Lymphoma, Hodgkin, classic (CHL) [MIM:236000] A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed-Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes. Disease susceptibility is associated with variants affecting the gene represented in this entry. A variant in the 5’-UTR of KLHDC8B, responsible for decreasing its expression, is associated with classic Hodgkin lymphoma and segregates with the disease in some families. A chromosomal aberration disrupting KLHDC8B has been found in a family with the nodular sclerosis type of Hodgkin lymphoma. Translocation t(2,3)(q11.2;p21.31).

RefSeq proteins (1): NP_775817* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006652	Kelch_1	Repeat
IPR015915	Kelch-typ_b-propeller	Homologous_superfamily
IPR051746	Kelch_domain_containing_8	Family

Pfam: PF01344, PF24681

UniProt features (9 total): repeat 8, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IXV7-F1	94.79	0.92

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 115 (showing top): GOBP_MITOTIC_CYTOKINESIS, MEF2_02, GOBP_CYTOKINETIC_PROCESS, GGCNKCCATNK_UNKNOWN, GOBP_ORGANELLE_FISSION, GOBP_CYTOKINESIS, NF1_Q6_01, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, GOBP_MITOTIC_NUCLEAR_DIVISION, GOBP_MITOTIC_CELL_CYCLE, GATA4_Q3, CTAWWWATA_RSRFC4_Q2, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, GOBP_NUCLEAR_CHROMOSOME_SEGREGATION, GOBP_CYTOSKELETON_DEPENDENT_CYTOKINESIS

GO Biological Process (4): nuclear chromosome segregation (GO:0098813), mitotic nuclear division (GO:0140014), mitotic cytokinetic process (GO:1902410), cell division (GO:0051301)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), cytosol (GO:0005829), midbody (GO:0030496), intercellular bridge (GO:0045171), cellularization cleavage furrow (GO:0110070)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
mitotic cell cycle	2
mitotic cell cycle process	2
chromosome segregation	1
nuclear division	1
mitotic cytokinesis	1
cytokinetic process	1
cellular process	1
binding	1
intracellular anatomical structure	1
cytoplasm	1
plasma membrane region	1

Protein interactions and networks

STRING

526 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KLHDC8B	BCL11A	Q9H165	648
KLHDC8B	CBFA2T3	O75081	647
KLHDC8B	PRR35	P0CG20	597
KLHDC8B	FAM133A	Q8N9E0	536
KLHDC8B	RRP36	Q96EU6	532
KLHDC8B	SPMIP7	A4D263	517
KLHDC8B	TRAPPC6B	Q86SZ2	500
KLHDC8B	TIGD3	Q6B0B8	499
KLHDC8B	CSF1	P09603	495
KLHDC8B	TOGARAM1	Q9Y4F4	492
KLHDC8B	KCNG3	Q8TAE7	477
KLHDC8B	KBTBD12	Q3ZCT8	473
KLHDC8B	SIPA1L2	Q9P2F8	472
KLHDC8B	AKR1C3	P42330	470
KLHDC8B	CSF1R	P07333	468

IntAct

28 interactions, top by confidence:

A	B	Type	Score
CCT2	TXNDC9	psi-mi:“MI:0914”(association)	0.730
PDCL3	PEX7	psi-mi:“MI:0914”(association)	0.640
CCT3	TXNDC9	psi-mi:“MI:0914”(association)	0.640
CCT5	TXNDC9	psi-mi:“MI:0914”(association)	0.640
CCT7	TXNDC9	psi-mi:“MI:0914”(association)	0.640
IMPDH1	BCAT2	psi-mi:“MI:0914”(association)	0.530
CCT7	PEX7	psi-mi:“MI:0914”(association)	0.530
ZNRD2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
Dlg4	KLHDC8B	psi-mi:“MI:0407”(direct interaction)	0.440
CCT3	C6orf11	psi-mi:“MI:0914”(association)	0.350
CCT7	C6orf11	psi-mi:“MI:0914”(association)	0.350
IMPDH1	LCMT2	psi-mi:“MI:0914”(association)	0.350
CCT2	WDR91	psi-mi:“MI:0914”(association)	0.350
NANOS1	CNOT1	psi-mi:“MI:0914”(association)	0.350
CCT5	TUBAL3	psi-mi:“MI:0914”(association)	0.350
CCT3	TUBAL3	psi-mi:“MI:0914”(association)	0.350
CCT7	WDR46	psi-mi:“MI:0914”(association)	0.350
SHOX	PBX1	psi-mi:“MI:0914”(association)	0.350
PDCL3	POTEF	psi-mi:“MI:0914”(association)	0.350
CAMK2D	PPM1D	psi-mi:“MI:0914”(association)	0.350
CD226	TMED7-TICAM2	psi-mi:“MI:0914”(association)	0.350
DNAJA2	ENC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS), KLHDC8B (Affinity Capture-MS)

ESM2 similar proteins: D4A2K4, O70277, O75382, O95294, P49593, P57775, Q08DS0, Q0D2K2, Q12788, Q2KJJ5, Q2TBI8, Q3U410, Q3USL1, Q4G0W2, Q501J2, Q5BK60, Q5E9V5, Q5RCW7, Q5RJL2, Q5SUV1, Q5U2W5, Q5XIA9, Q5ZJ37, Q6PF15, Q6RFH5, Q8BGY4, Q8BNV1, Q8BSF5, Q8C3F7, Q8C4J7, Q8IXV7, Q8IYD2, Q8IZ69, Q8K1S1, Q8N135, Q8NEP7, Q8WU66, Q91XA8, Q96AZ1, Q96I51

Diamond homologs: Q5E9V5, Q5RCW7, Q5XIA9, Q8IXV7, Q8IYD2, Q8N239, Q91XA8, Q9D2D9, O14682, Q0WW40, Q4KLM4, Q6DFF7, Q8R2P1, Q9H0H3, Q0D2A9, Q6NRH0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 28 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of tubulin folding intermediates by CCT/TriC	5	124.4×	3e-08
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding	5	120.0×	3e-08
Chaperonin-mediated protein folding	5	88.4×	8e-08
Protein folding	5	76.3×	1e-07

GO biological processes:

GO term	Partners	Fold	FDR
protein folding	5	20.7×	1e-04
protein stabilization	5	13.4×	8e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

192 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	114
Likely benign	61
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

649 predictions. Top by Δscore:

Variant	Effect	Δscore
3:49171682:GCGG:G	donor_gain	1.0000
3:49172780:G:GT	donor_gain	1.0000
3:49174237:A:AG	acceptor_gain	1.0000
3:49174237:AGAT:A	acceptor_gain	1.0000
3:49174238:G:GG	acceptor_gain	1.0000
3:49174238:GATG:G	acceptor_gain	1.0000
3:49174962:GCATG:G	donor_gain	1.0000
3:49174966:GGTGA:G	donor_loss	1.0000
3:49174967:G:T	donor_loss	1.0000
3:49174968:T:A	donor_loss	1.0000
3:49175099:GGA:G	donor_gain	1.0000
3:49171681:GGCGG:G	donor_gain	0.9900
3:49171682:GCGGG:G	donor_gain	0.9900
3:49171683:CGGGT:C	donor_loss	0.9900
3:49171684:GG:G	donor_gain	0.9900
3:49171684:GGGT:G	donor_loss	0.9900
3:49171685:GG:G	donor_gain	0.9900
3:49171685:GGTGA:G	donor_loss	0.9900
3:49171686:G:GG	donor_gain	0.9900
3:49171687:T:G	donor_loss	0.9900
3:49174234:TGCAG:T	acceptor_loss	0.9900
3:49174235:GCA:G	acceptor_loss	0.9900
3:49174236:CA:C	acceptor_loss	0.9900
3:49174238:G:A	acceptor_loss	0.9900
3:49174238:GAT:G	acceptor_gain	0.9900
3:49174967:G:GG	donor_gain	0.9900
3:49175060:AG:A	acceptor_gain	0.9900
3:49175061:GG:G	acceptor_gain	0.9900
3:49171714:G:T	donor_gain	0.9800
3:49172631:TCCA:T	acceptor_loss	0.9800

AlphaMissense

2265 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:49174804:T:A	W202R	0.998
3:49174804:T:C	W202R	0.998
3:49174806:G:C	W202C	0.998
3:49174806:G:T	W202C	0.998
3:49174840:T:C	F214L	0.998
3:49174842:T:A	F214L	0.998
3:49174842:T:G	F214L	0.998
3:49174930:T:C	F244L	0.997
3:49174932:T:A	F244L	0.997
3:49174932:T:G	F244L	0.997
3:49175108:G:C	R271S	0.997
3:49175108:G:T	R271S	0.997
3:49175154:G:T	G287W	0.997
3:49175155:G:A	G287E	0.997
3:49175663:G:C	W309C	0.997
3:49175663:G:T	W309C	0.997
3:49173090:G:C	W107C	0.996
3:49173090:G:T	W107C	0.996
3:49174876:A:C	S226R	0.996
3:49174878:C:A	S226R	0.996
3:49174878:C:G	S226R	0.996
3:49174883:G:A	G228D	0.996
3:49174931:T:C	F244S	0.996
3:49175661:T:A	W309R	0.996
3:49175661:T:C	W309R	0.996
3:49174840:T:A	F214I	0.995
3:49174883:G:T	G228V	0.995
3:49174886:G:A	G229D	0.995
3:49175067:T:A	W258R	0.995
3:49175067:T:C	W258R	0.995

dbSNP variants (sampled 300 via entrez): RS1000172589 (3:49176504 T>G), RS1000315059 (3:49171639 G>A), RS1000620034 (3:49174220 A>G), RS1000667106 (3:49171874 C>A,T), RS1000690219 (3:49176203 G>A), RS1002826752 (3:49170001 G>A), RS1003064599 (3:49176744 G>A,T), RS1003123054 (3:49173761 G>T), RS1003455186 (3:49172057 G>A), RS1003660451 (3:49175288 C>T), RS1004244169 (3:49175359 C>T), RS1005659224 (3:49176912 C>A), RS1005936169 (3:49176275 G>A), RS1006529222 (3:49169644 C>T), RS1006571788 (3:49170551 T>C)

Disease associations

OMIM: gene MIM:613169 | disease phenotypes: MIM:236000

GenCC curated gene-disease

Disease	Classification	Inheritance
classic Hodgkin lymphoma	Limited	Autosomal dominant

Mondo (1): classic Hodgkin lymphoma (MONDO:0009348)

Orphanet (1): Classic Hodgkin lymphoma (Orphanet:391)

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0003347	Impaired lymphocyte transformation with phytohemagglutinin
HP:0003459	Polyclonal elevation of IgM
HP:0012189	Hodgkin lymphoma

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST000880_30	Menarche (age at onset)	3.000000e-08
GCST003818_48	Resting heart rate	3.000000e-13
GCST004131_23	Inflammatory bowel disease	1.000000e-33
GCST004132_17	Crohn’s disease	3.000000e-23
GCST004133_11	Ulcerative colitis	8.000000e-20
GCST007387_40	Insomnia symptoms (never/rarely vs. sometimes/usually)	5.000000e-09
GCST007388_28	Insomnia symptoms (never/rarely vs. usually)	2.000000e-09
GCST008840_1	Depressive symptom (depressed mood) (binary trait)	8.000000e-10
GCST010698_80	Subcortical volume (min-P)	3.000000e-24
GCST010699_110	Brain morphology (min-P)	4.000000e-08
GCST010701_52	Cortical surface area (MOSTest)	1.000000e-16
GCST010702_36	Subcortical volume (MOSTest)	1.000000e-10
GCST010703_262	Brain morphology (MOSTest)	2.000000e-13
GCST90020024_1147	A body shape index	2.000000e-08

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0007876	insomnia measurement
EFO:0007006	depressive symptom measurement
EFO:0004346	neuroimaging measurement
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	5
Benzo(a)pyrene	increases expression, decreases expression, decreases methylation	4
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
Air Pollutants	increases abundance, decreases expression	2
Estradiol	affects cotreatment, decreases expression	2
Nickel	decreases expression	2
Cyclosporine	decreases expression	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression, increases methylation	1
trichostatin A	decreases expression	1
sodium arsenite	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Decitabine	affects expression	1
Cadmium	increases abundance, increases expression	1
Cisplatin	affects expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Doxorubicin	increases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Methyl Methanesulfonate	increases expression	1
Niclosamide	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Triclosan	decreases expression	1

Clinical trials (associated diseases)

101 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02166463	PHASE3	ACTIVE_NOT_RECRUITING	Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02661503	PHASE3	ACTIVE_NOT_RECRUITING	HD21 for Advanced Stages
NCT02684708	PHASE3	COMPLETED	Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
NCT03907488	PHASE3	ACTIVE_NOT_RECRUITING	Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT04342936	PHASE3	UNKNOWN	Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT04486391	PHASE3	TERMINATED	Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
NCT05518318	PHASE3	UNKNOWN	GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin’s Lymphoma (R/R cHL)
NCT05711628	PHASE3	WITHDRAWN	A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
NCT06465446	PHASE3	NOT_YET_RECRUITING	A Study of IMM01 Plus Tiselizumab Versus Physician’s Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
NCT00654732	PHASE2	COMPLETED	Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
NCT00742027	PHASE2	COMPLETED	Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin’s Lymphoma
NCT00967369	PHASE2	COMPLETED	Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
NCT02164500	PHASE2	COMPLETED	JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
NCT02414568	PHASE2	COMPLETED	Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
NCT02758717	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
NCT02824029	PHASE2	COMPLETED	Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02940301	PHASE2	ACTIVE_NOT_RECRUITING	Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03004833	PHASE2	COMPLETED	Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
NCT03057795	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
NCT03209973	PHASE2	COMPLETED	A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03226249	PHASE2	UNKNOWN	PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
NCT03233347	PHASE2	ACTIVE_NOT_RECRUITING	Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
NCT03480334	PHASE2	ACTIVE_NOT_RECRUITING	Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
NCT03527628	PHASE2	UNKNOWN	OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy
NCT03580564	PHASE2	COMPLETED	An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin’s Lymphoma
NCT03652441	PHASE2	COMPLETED	Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
NCT03655483	PHASE2	UNKNOWN	Study of GLS-010 Injection in the Treatment of Classical Hodgkin’s Lymphoma
NCT03712202	PHASE2	ACTIVE_NOT_RECRUITING	Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
NCT04067037	PHASE2	ACTIVE_NOT_RECRUITING	Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin’s Lymphoma
NCT04318080	PHASE2	COMPLETED	Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT04510636	PHASE2	RECRUITING	Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
NCT04624984	PHASE2	UNKNOWN	PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL
NCT04788043	PHASE2	ACTIVE_NOT_RECRUITING	Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
NCT04837859	PHASE2	RECRUITING	Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
NCT04838652	PHASE2	RECRUITING	Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
NCT05008224	PHASE2	COMPLETED	Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
NCT05039073	PHASE2	RECRUITING	Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
NCT05179603	PHASE2	TERMINATED	A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
NCT05404945	PHASE2	ACTIVE_NOT_RECRUITING	Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
NCT05900765	PHASE2	RECRUITING	A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin’s Lymphoma